Skip to main content
. 2016 May 3;353:i2231. doi: 10.1136/bmj.i2231

Table 1.

Characteristics of included studies

References Study duration (weeks) Intervention, daily dose (No of patients) Associated sulphonylureas Mean haemoglobin A1c at baseline (%) Mean age of participants (years) Male (%) Definition of hypoglycaemia
Barnett et al27 24 Linagliptin 5 mg (n=95) or placebo (n=43) Sulphonylureas, not specified DPP-4 inhibitors: 7.8, placebo: 7.7* DDP-4 inhibitors: 75, placebo: 75* DDP-4 inhibitors: 72, placebo: 62* Plasma glucose ≤3.9 mmol/L, with or without symptoms
Chacra et al45 24 Saxagliptin 2.5 mg (n=248), saxagliptin 5 mg (n=253), or placebo (n=267) Glyburide DDP-4 inhibitors: 8.4-8.5, placebo: 8.4 DDP-4 inhibitors: 55, placebo: 55 DDP-4 inhibitors: 45, placebo: 46 NR
Garber et al46 24 Vildagliptin 50 mg (n=170) or 100 mg (n=169), or placbeo (n=176) Glimepiride DDP-4 inhibitors: 8.5-8.6, placebo: 8.5 DDP-4 inhibitors: 58-59, placebo: 58 DDP-4 inhibitors: 59, placebo: 58 Symptomatic hypoglycaemia confirmed by self monitored blood glucose <3.1 mmol/L
Hermansen et al47 24 Sitagliptin 100 mg (n=222) or placebo (n=219) Glimepiride DDP-4 inhibitors: 8.3, placebo: 8.3 DDP-4 inhibitors: 56, placebo: 56.5 DDP-4 inhibitors: 53, placebo: 53 NR, but hypoglycaemia is included in adverse events of special interest
Kikuchi et al48 12 Vildagliptin 100 mg (n=102) or placebo (n=100) Glimepiride DDP-4 inhibitors: 7.8, placebo: 8.0 DDP-4 inhibitors: 59, placebo: 60 DDP-4 inhibitors: 73.5, placebo: 69 Symptomatic hypoglycaemia, confirmed by self monitored blood glucose <3.1 mmol/L
Lewin et al49 18 Linagliptin 5 mg (n=161) or placebo (n=84) Sulphonylureas, not specified DDP-4 inhibitors: 8.6, placebo: 8.6 DDP-4 inhibitors: 57, placebo: 56 DDP-4 inhibitors: 48, placebo: 62 NR, but hypoglycaemia was recorded and analysed separately from other adverse events
Owens et al50 24 Linagliptin 5 mg (m=792) or placebo (m=263) Sulphonylureas, not specified DDP-4 inhibitors: 8.1, placebo: 8.1 DDP-4 inhibitors: 58, placebo: 58 DDP-4 inhibitors: 48, placebo: 47 NR
Pratley et al 51 26 Alogliptin 12.5 mg (n=203), alogliptin 25 mg (n=198), or placebo (m=99) Glyburide NR DDP-4 inhibitors: 56.5, placebo: 57 DDP-4 inhibitors: 52, placebo: 51.5 Symptomatic hypoglycaemia with blood glucose <3.3 mmol/L or <2.8 mmol/L without symptoms
Seino et al52 12 Alogliptin 12.5 mg (n=105), alogliptin 25 mg (n=104), or placebo (n=103) Glimepiride DDP-4 inhibitors: 8.5%, placebo: 8.6% DDP-4 inhibitors: 60, placebo: 60 DDP-4 inhibitors: 66, placebo: 69 NR
White et al53 76† Alogliptin any doses (n=1198), or placebo (n=1172) Sulphonylureas, not specified DDP-4 inhibitors: 8.0, placebo: 8.0* DDP-4 inhibitors: 61, placebo: 61‡ DDP-4 inhibitors: 68, placebo: 69* NR

DDP-4=dipeptidyl peptidase-4; haemoblobin A1c =glycated haemoglobin; NR=not reported.

*Data refer to overall study population, not only to patients treated with sulphonylureas.

†Median use (weeks) for patients treated with alogliptin.

‡Median age (years).